ShanX Medtech B.V. (SXM), an innovative Dutch startup transforming microbial infection management, has announced the closing of an oversubscribed €15 million (~$17.5 million) seed funding round. The financing combines equity, grants, and the Innovatiekrediet, with equity investment led by Borski Fund, NextGen Ventures, CbusineZ, Brabantse Ontwikkelings Maatschappij (BOM), Invest-NL, and a strategic angel fund. This round, together with a recent €8.85 million (~$10.4 million) European Commission contract, brings the company’s total funding to $28 million.
Addressing a Critical Global Health Challenge
The raised capital will accelerate the final development, clinical validation, regulatory approval, and commercial launch of ShanX’s novel In-Vitro Diagnostic (IVD) platform. This innovation directly tackles the global healthcare threat posed by antimicrobial resistance (AMR), which continues to escalate and strain health systems worldwide. With growing interest from both healthcare providers and commercial partners, the SXM platform promises to change how infections are diagnosed and treated.
A Breakthrough in Rapid Antimicrobial Susceptibility Testing
ShanX Medtech’s platform enables ultra-rapid, direct-from-sample antimicrobial susceptibility testing (AST) by monitoring microbial metabolism with innovative chemistry. Unlike traditional methods that require multiple technicians and days to deliver results, SXM produces comprehensive, actionable results within an hour and with minimal user involvement. This speed allows clinicians to make timely, evidence-based treatment decisions in laboratories and at the point of care.
Impact on Patient Care and Healthcare Systems
By reducing the time to accurate diagnostics, ShanX’s technology has the potential to improve patient outcomes, lower healthcare costs, and curb the spread of resistant infections. The platform also contributes to pandemic preparedness by enabling faster responses to emerging microbial threats. Its broad clinical applicability could transform infection management across multiple healthcare settings.
Founder’s Vision and Motivation
Dr. Sophia E. Shanko, founder and CEO of ShanX Medtech, explained that the company was inspired by a single patient story highlighting the consequences of delayed diagnostics. “Our vision is to equip every clinician with the ability to act decisively, guided by diagnostic evidence in real-time,” she said. According to Shanko, the latest funding significantly accelerates the path toward making ultra-rapid AST accessible in both laboratory and point-of-care environments.
Investor Confidence and Strategic Support
Investors are backing ShanX Medtech’s technology and execution capabilities with confidence. Simone Brummelhuis, Partner at Borski Fund, emphasized that the company’s technology is best-in-class and initially targets women’s health applications, such as urinary tract infections. Paul Vernooij, Investment Manager at BOM, added that the technology is highly innovative and addresses one of the most critical unmet needs in global healthcare, reflecting strong potential for preventive impact.
About ShanX Medtech
Founded in 2019 and headquartered at Eindhoven’s High Tech Campus, ShanX Medtech develops ultra-rapid IVD solutions to support global efforts against AMR. Eindhoven’s MedTech ecosystem, which hosts over 350 companies and accounts for 90% of Dutch MedTech patents, provides the research, manufacturing, and entrepreneurial infrastructure that accelerates innovations like ShanX. The company aims to deliver faster, simpler, and more accessible diagnostics to improve public health worldwide.
With a total of $28 million in funding and multi-million-euro commercial contracts, ShanX Medtech is poised to transform infection diagnostics and patient care. Its platform promises to shorten diagnostic timelines, enable evidence-based treatments, and strengthen global responses to antimicrobial threats. As the company moves closer to commercialization, it stands at the forefront of a new era in rapid, actionable healthcare diagnostics.